MiNK Therapeutics to Present Three Abstracts on Novel Allogeneic iNKT Programs at SITC
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced acceptance of three abstracts for presentation at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held between November 10-14, 2021.
Presentation Details:
Abstract title: Persistence and tissue distribution of AgenT-797 – a native allogeneic iNKT cell-therapy drug product (NCT04582201 and NCT04754100)Abstract number: 400Presenting author: Marco Purbhoo
Abstract title: AgenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models Abstract number: 205Presenting author: Burcu Yigit
Abstract title: Identification and characterization of an allogeneic iNKT-CAR targeting BCMAAbstract number: 135Presenting author: Xavier Michelet
The full abstracts will be released on Tuesday, November 9, 2021. The updated data will be presented at the conference and will become available in the investor section of our website at http://investor.minktherapeutics.com following the presentation on November 12, 2021.
About MiNK TherapeuticsMiNK Therapeutics is a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/ and follow MiNK on LinkedIn and Twitter @MiNK_iNKT.
ContactMiNK Therapeutics Kimberly HaKKH Advisors917-291-5744[email protected]
Source: MiNK TherapeuticsSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PEACE CORPS AND AMERICORPS USHER IN A NEW ERA OF SERVICE
- The Michaels Organization Hosts Ribbon Cutting for New Affordable Multifamily Community in Fort Lupton, CO
- BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Closes $8.4M Private Placement
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!